Core Laboratories Inc. CLB
10.39
(0.10)
(0.95%)
as of 25 Sep
- Market cap
- $481.3M
- P/E
- 20.0×
Follow CLB
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.39 | 27.06 | 25.03 | 18.18 |
+8 more quarters Free account |
P/S ratio |
1.03 | 1.47 | 1.41 | 1.10 | |
P/FCF ratio |
36.64 | 35.83 | 29.38 | 15.23 | |
P/Operating CF |
68.67 | 195.10 | 93.66 | 67.26 | |
P/B ratio |
1.92 | 2.81 | 2.73 | 2.06 | |
Price to Tangible BV |
3.23 | 4.76 | 4.67 | 3.34 | |
EV/Sales |
1.23 | 1.67 | 1.60 | 1.30 | |
EV/EBITDA |
10.19 | 12.77 | 11.85 | 9.67 | |
EV/Operating CF |
22.62 | 25.52 | 22.76 | 13.51 | |
EV/FCF |
43.62 | 40.59 | 33.28 | 17.88 | |
Quick Ratio |
1.37 | 1.32 | 1.35 | 1.57 | |
Current Ratio |
2.12 | 2.05 | 2.02 | 2.37 | |
Net Debt/EBITDA |
7.02 | 16.22 | 4.49 | 3.61 | |
Debt/Assets |
19.40% | 19.47% | 18.88% | 19.30% | |
Debt/Equity |
0.41 | 0.42 | 0.41 | 0.41 | |
Asset Turnover |
0.87 | 0.89 | 0.90 | 0.87 | |
Operating CF/Net income |
1.31 | (5.03) | 1.61 | 0.60 | |
Capex/Depreciation |
(1.09) | (0.90) | (0.85) | (0.80) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.79% | 12.08% | 7.69% | 7.95% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.19 | 0.18 | |
Share Based Compensation of Revenue |
0.72% | 4.13% | 0.81% | 0.99% | |
Graham Net Nets |
(0.17) | (0.13) | (0.13) | (0.15) | |
Graham Number |
8.42 | 9.13 | 9.19 | 9.58 | |
Earnings Yield |
4.47% | 3.70% | 4.00% | 5.50% | |
Free Cash Flow Yield |
2.73% | 2.79% | 3.40% | 6.57% | |
Revenue per Share |
2.71 | 2.64 | 2.98 | 2.91 | |
Operating CF per Share |
0.17 | 0.09 | 0.17 | 0.18 | |
Capex per Share |
(0.09) | (0.07) | (0.07) | (0.06) | |
Free Cash Flow per Share |
0.08 | 0.01 | 0.10 | 0.12 | |
Cash per Share |
0.49 | 0.50 | 0.49 | 0.55 | |
Shareholders Equity per Share |
6.06 | 5.97 | 5.86 | 6.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.06 | 5.97 | 5.86 | 6.00 | |
Free Cash Flow |
3.63 | 0.57 | 4.81 | 5.62 | |
Working Capital |
113.31 | 109.64 | 108.65 | 131.17 | |
Capital Expenditures |
(4.18) | (3.39) | (3.13) | (2.88) | |
Net Current Asset Value |
(93.65) | (98.21) | (97.14) | (87.06) | |
EV/EBIT |
13.36 | 16.25 | 14.93 | 12.25 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Net Profit Margin |
4.78% | (0.65%) | 3.58% | 10.58% | |
Price to Operating Income |
11.22 | 14.34 | 13.18 | 10.43 | |
| Other line items | |||||
Average Receivables |
122.02 | 123.09 | 121.44 | 128.67 | |
Average Payables |
40.93 | 39.24 | 35.91 | 35.29 | |
Average Inventory |
58.87 | 58.41 | 56.95 | 61.87 | |
Average Assets |
594.44 | 589.62 | 584.57 | 595.91 | |
Average Common Equity |
273.04 | 267.25 | 262.26 | 266.90 |
Columns are period end dates